Merck KGaA Forecasts Earnings, Sales Growth
Merck’s lupus drug enpatoran has failed to meet the primary endpoint in a subgroup of patients, but the drug's development is ...
Stephen Krahling was a published cancer researcher when vaccine maker Merck brought him on board as a virologist in 1999. That’s when he says he found himself embroiled in an all-hands-on-deck ...
The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.
Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...
Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...
Shares in pharmaceuticals giant Merck (MRK) weakened today on fears that a patent battle could jeopardize its plans to sell a ...
What we want to do is remove about 0.35 acres of current site wetlands, in exchange for wetlands that are already in place, ...
Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and ...
Scientist Stephen Krahling worked on a project at Merck called “Protocol 7” and was uniquely positioned to blow the whistle on what he learned.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback